title: Community experience of vemurafenib for BRAF(V600) melanoma.
authors.affiliation: Kolling Institute, and Melanoma Institute of Australia, University of Sydney, NSW 2065, Australia. Electronic address: peter.hersey@sydney.edu.au.
authors.forename: Peter
authors.initials: P
authors.lastname: Hersey
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf